בליאומיצין PFI

Country: Iżrael

Lingwa: Ebrajk

Sors: Ministry of Health

Ingredjent attiv:

BLEOMYCIN SULFATE

Disponibbli minn:

MEGAPHARM LTD

Kodiċi ATC:

L01DC01

Għamla farmaċewtika:

אבקה להכנת תמיסה לזריקה

Kompożizzjoni:

BLEOMYCIN SULFATE 15000 IU/VIAL

Rotta amministrattiva:

לתוך קרום הריאה, תוך-עורקי, תוך-ורידי, תת-עורי, תוך-שרירי, לתוך בקע

Tip ta 'preskrizzjoni:

מרשם נדרש

Manifatturat minn:

BAXTER ONCOLOGY GmbH, GERMANY

Grupp terapewtiku:

BLEOMYCIN

Żona terapewtika:

BLEOMYCIN

Indikazzjonijiet terapewtiċi:

Bleomycin is useful in the management of the following neoplasms: Squamous cell carcinoma affecting the mouth, nasopharynx and paranasal sinuses, larynx, oesaphagus, cervix, vagina, penis and skin. Well differentiated tumors usually respond better than anaplastic ones.Hodgkin's disease and other malignant lymphomas, including mycosis fungoides. Testicular carcinoma (seminoma and no seminoma) .Malignant effusions of serous cavities (intrapleural and intraperitoneal).Secondary indications in which bleomycin has been shown to be of some value include metastatic malignant melanoma, carcinoma of the thyroid lung and bladder. Local treatment of refractory warts. Bleomycin can be used as a single agent, but is generally used in combination with other cytotoxics and/or with radiation therapy.

Data ta 'l-awtorizzazzjoni:

2020-09-30